This company listing is no longer active
A8C1 Stock Overview
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Abcam plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$13.70 |
52 Week High | US$17.70 |
52 Week Low | US$12.20 |
Beta | 0.78 |
1 Month Change | 0% |
3 Month Change | -8.67% |
1 Year Change | -14.85% |
3 Year Change | -18.26% |
5 Year Change | 0.74% |
Change since IPO | 268.38% |
Recent News & Updates
Recent updates
Shareholder Returns
A8C1 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0% | 4.2% | -0.6% |
1Y | -14.9% | -13.8% | 4.9% |
Rentabilidad frente al sector: A8C1 underperformed the German Biotechs industry which returned 7.6% over the past year.
Rentabilidad vs. Mercado: A8C1 underperformed the German Market which returned -13% over the past year.
Price Volatility
A8C1 volatility | |
---|---|
A8C1 Average Weekly Movement | 8.0% |
Biotechs Industry Average Movement | 5.0% |
Market Average Movement | 4.7% |
10% most volatile stocks in DE Market | 9.6% |
10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: A8C1 has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: A8C1's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 1,682 | Alan Hirzel | https://www.abcam.com |
Abcam plc Fundamentals Summary
A8C1 fundamental statistics | |
---|---|
Market cap | €3.47b |
Earnings (TTM) | €8.31m |
Revenue (TTM) | €398.69m |
417.8x
P/E Ratio8.7x
P/S RatioIs A8C1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A8C1 income statement (TTM) | |
---|---|
Revenue | UK£350.40m |
Cost of Revenue | UK£89.90m |
Gross Profit | UK£260.50m |
Other Expenses | UK£253.20m |
Earnings | UK£7.30m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | 0.032 |
Gross Margin | 74.34% |
Net Profit Margin | 2.08% |
Debt/Equity Ratio | 16.4% |
How did A8C1 perform over the long term?
See historical performance and comparison